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Abstract
Introduction—Cytolethal distending toxin (Cdt) is potentially one of several virulence factors of
Aggregatibacter actinomycetemcomitans, the prime etiological agent of localized aggressive
periodontitis (LAP). Little is known regarding the Cdt-specific antibody response in humans. The
current study is a quantitative and qualitative evaluation of the toxin-specific antibody response in a
cohort of LAP patients and age-, race- and sex-matched controls.
Methods—Ninety-five subjects provided a total of 692 serum samples. Sera were analysed by
enzyme-linked immunosorbent assays to determine the titers of antibody against the intact Cdt
holotoxin as well as the individual subunit proteins (CdtA, CdtB, and CdtC). Neutralization of growth
inhibition mediated by Cdt was evaluated in a modified colony-forming assay using Chinese hamster
ovary cells.
Results—Fourteen of the 95 subjects exhibited significant serum Cdt-binding activity. There were
no differences in the percentages of seropositive individuals or in the mean antibody titers between
the control and LAP groups. Binding activity was detected against each of the three Cdt subunit
proteins in all of the positive samples. Neutralization of Cdt-mediated growth inhibition was detected
in samples from all of the seropositive subjects (range 20–75%).
Conclusions—Cdt, a recently identified A. actinomycetemcomitans virulence factor, is capable of
inducing a neutralizing antibody response indicating that the toxin is produced during natural
infection of humans. The failure of a vast majority (20 of 23) of the LAP subjects to mount a
significant anti-Cdt response may in part explain their relative susceptibility to the disease.
Keywords
Aggregatibacter (Actinobacillus) actinomycetemcomitans; antibody; cytolethal distending toxin;
localized aggressive periodontitis
Aggregatibacter actinomycetemcomitans is a gram-negative coccobacillus that is believed to
be a primary etiological agent of localized aggressive periodontitis (LAP) (16). LAP is a
relatively rare form of periodontal disease that occurs at a higher incidence in African
Americans relative to other racial groups within the United States (17). A.
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actinomycetemcomitans produces a number of virulence factors including adhesins, endotoxin
[lipopolysaccharide (LPS)], leukotoxin (Lkt), and cytolethal distending toxin (Cdt) (7,28).
Certain of these factors facilitate colonization of the periodontal microenvironment, others are
proinflammatory and still others act in an immunomodulatory fashion. Collectively, many of
these molecules have been implicated as playing a role in the pathogenesis of LAP. A large
body of data suggests that inherited anomalies in host immunity to bacterial infection may
regulate susceptibility to LAP. Despite this knowledge, the role of specific A.
actinomycetemcomitans virulence factors and the acquired immune responses they elicit in the
pathogenesis of LAP remain unclear.
Virtually all LAP patients have been shown to mount a humoral immune response against at
least one of a variety of A. actinomycetemcomitans antigens including LPS, outer membrane
proteins, pili/fimbriae, exopolysaccharides (serotype antigens), and Lkt (14). In general, LAP
patients were typically found to have higher titers of antibody relative to appropriate control
populations. This has been observed with respect to antibody binding to intact bacterial cells
as well as purified virulence factors including LPS and Lkt (4,21,25). The purely quantitative
nature of these data and the cross-sectional manner in which they were collected make it very
difficult to determine whether the antibodies found in LAP patients are protective, destructive,
or irrelevant in terms of disease pathogenesis. Therefore, to delineate the role of antibodies
directed against bacterial virulence factors in disease regression and/or progression it is
necessary to evaluate not only the magnitude of the humoral response but also the functional
attributes of the antibody molecules. Although there are studies addressing this issue relative
to other A. actinomycetemcomitans virulence factors the literature contains minimal
information regarding the humoral immune response against Cdt.
The Cdt is a recently characterized genotoxin that blocks cell cycle progression in specific
classes of eukaryotic cells and cell lines. The toxin is a heterotrimer structurally similar to A–
B-type toxins. The Cdt holotoxin is made up of three subunit proteins designated CdtA, CdtB,
and CdtC. Several other pathogenic bacterial species produce a Cdt including Escherichia
coli (10), Helicobacter hepaticus (2), Haemophilus ducreyi (5,22), Campylobacter jejuni (8)
and Shigella spp. (11). The Cdt has, to date, only been found in A. actinomycetemcomitans
among bacterial species indigenous to the human oral cavity (29). Several types of oral
epithelial cells and T lymphocytes are particularly susceptible to the A.
actinomycetemcomitans Cdt. In contrast, human periodontal ligament cells and gingival
fibroblasts seem considerably less vulnerable to the toxin (3,12). Therefore, expression of this
relatively unique secreted bacterial virulence factor may in part play a role in the close
association between A. actinomycetemcomitans and LAP. This association is supported by the
recent work of Tan et al. (27) showing that a majority of diseased sites examined (77%) in LAP
patients contained A. actinomycetemcomitans strains that were of the cdt+ genotype.
Very little is known regarding the significance of Cdt-specific antibodies with respect to the
pathogenesis of LAP. Thus, in the current study we evaluated the Cdt-specific humoral immune
response in a cohort of LAP patients. The primary goal of this study was to test the hypothesis
that subjects with a history of LAP or active LAP mount a quantitatively greater antibody
response to Cdt than age-, race- and sex-matched controls. Secondarily, we attempted to
characterize qualitatively the fine antigen specificity and functional activity of antibodies
produced by these two groups of subjects.
Materials and methods
Study population
Serum samples were obtained from 95 of the 118 family members and control subjects who
participated in an earlier study described in DiRienzo et al. (6). Sufficient amounts of serum
Xynogala et al. Page 2
Oral Microbiol Immunol. Author manuscript; available in PMC 2009 August 26.
for analysis were not available from the remaining 23 individuals. Twenty-one of the families
had at least one member (child or adult) with clinical signs of LAP or a history of the disease
and at least one sibling 13 years old or younger with no clinical evidence of LAP. The siblings
with no periodontal disease were defined as the LAP-susceptible individuals and the persons
with a history of disease or active disease were defined as the probands. Individuals from
families with no history of LAP were also included as healthy controls and were matched by
age, sex and race to the disease-susceptible subjects. There were a total of 48 male participants
(baseline ages 6–41 years) and 47 female (baseline ages 7–42 years) participants. At the
initiation of the study 76 of the subjects were periodontally healthy (62 of whom were under
18 years of age), 11 were diagnosed with LAP and eight with chronic periodontitis. Clinical
examinations were conducted and blood samples were drawn periodically throughout the 7-
year evaluation period. The number of blood draws varied between subjects depending upon
the time of their entry into the study and their compliance with appointment dates (ranging
from 1 to 28 samples per subject). Patients received treatment as deemed necessary. The clinical
examination included evaluation of the plaque index, gingival index, probing depths, clinical
attachment levels, and furcation involvement. Full-mouth radiographs were taken at the
baseline visit and supplemented with bitewing and/or peri-apical radiographs as needed at
subsequent visits. Based on the results of sequential examinations a change in status from
periodontal health to LAP was referred to as a conversion. Such an event was defined as an
increase of 2 mm or more relative to the baseline level in the distance measured from the
cementoenamel junction to the bottom of the periodontal pocket or an increase of at least 2
mm in probing depth associated with the permanent incisors and or first molars. This change
was confirmed over a 3-month interval and had to coincide with a loss of clinical attachment
greater than or equal to 1 mm in relation to the baseline examination. Based on these criteria,
12 subjects developed LAP over the course of the 7-year study. Sera were isolated from blood
drawn during this time and stored at −20°C. A total of 692 serum samples from the 95 subjects
were analysed in this study. The serum samples were identified by coded numbers from 1 to
692 and the determination of anti-Cdt antibody titers was performed in a blinded manner.
Isolation of recombinant Cdt extracts and subunit protein antigens
Escherichia coli BL21(DE3) F− ompT hsdSB (rB− mB−) gal dcm (DE3) (pET15bCdt) was
cultured in 10 ml of Luria Bertani medium containing 50 μg/ml ampicillin and grown overnight
with vigorous shaking at 37°C as described previously (19). Briefly, bacterial suspensions were
sonicated for 1 min at 4°C (Braun, Norwalk, CT), then centrifuged at 12,000 g for 10 min
(Spinco model SS-34 rotor) to remove unbroken cells and sterilized by passage through a 0.22-
μm pore-size filter (Whatman Inc, Clifton NJ). The Micro BCA protein assay kit (Pierce, IL)
was used to determine total protein concentration.
Recombinant clones E. coli BL-21(DE3) (pET15bCdtA), E. coli BL-21(DE3) (pET15bCdtB),
and E. coli BL-21(DE3) (pET15bCdtC) were used to prepare the three amino-terminal
histidine-tagged wild-type His6-CdtA, His6-CdtB and His6-CdtC proteins, respectively (18).
The proteins were obtained from isopropyl β-D-1-thiogalactopyranoside-induced cultures by
affinity chromatography on nickel-iminodiacetic acid columns (EMD Chemicals [Novagen],
Gibbstown, NJ) as described previously (18). Yields averaged 25–30 μg protein/ml of culture.
The final protein preparations were dialysed to remove urea while promoting protein refolding,
passed through 45-μm filters and quantified with the Micro BCA protein assay kit (Pierce,
Rockville, IL). Purity was assessed by analysis on 10–20% sodium dodecyl sulfate–
polyacrylamide gels (BioRad, Hercules, CA) stained with Coomassie Brilliant Blue. Aliquots
of the quantified protein samples were stored at −70°C in a buffer containing 10 mM Tris–HCl
(pH 7), 100 mM NaCl, 5 mM MgCl2, and 5 mM imidazole. The proteins were also analysed
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis as previously described (15).
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Briefly, the samples were run at a room temperature in a 10–20% Tris–HCl Ready Gel (Bio-
Rad) at 100 V. The gel was stained with Coomassie Blue for 1 h and then analysed.
Preparation of reconstituted toxin
Cdt was reconstituted in vitro by mixing equimolar concentrations of the individual subunit
proteins in a coating buffer containing 0.1 M NaHCO3 (pH 8.6) and incubated at 4°C for at
least 1.5 h.
Enzyme-linked immunosorbent assays (ELISA)
To determine serum antibody titers either the reconstituted recombinant Cdt (0.5 μg/well) or
individual subunit proteins (166 ng/well) in 0.1 M NaHCO3 (pH 8.6) were used to coat 96-
well microtiter plates overnight at 4°C. The plates were then washed three times with 0.1%
phosphate-buffered saline (PBS) Tween-20 in an automatic washer (Ultrawash Plus, Dyna-
tech Laboratories, Chantilly, VA). Blocking buffer (1% bovine serum albumin, 0.02%
NaN3) was added and the plates were incubated for 1 h. The plates were washed three times.
Sera were serially diluted from 1/100 to 1/3200 in 0.1% PBS-Tween 20 and the dilutions were
added to triplicate wells. The plates were incubated for 1 h and washed three times. Bound
human immunoglobulin G (IgG) was detected with a monoclonal antibody (mAb) anti-human
IgG alkaline phosphatase conjugate (Amersham Biosciences, Piscataway, NJ) at 1/5000 and
1/25,000 dilutions in 0.1% PBS-Tween 20 for 1 h. The working dilutions of the anti-human
IgG mAb were determined in preliminary experiments by obtaining titration curves. All
incubations were performed in a humid atmosphere at 37°C. The plates were washed and
developed using SIGMA FAST™ p-nitrophenylphosphate tablet sets (pNPP alkaline
phosphatase substrate) in the dark for 30 min. A 1 M NaOH stop solution (30 μl/well) was
added and the absorbance was read at 405 nm in an HTS 7000 BioAssay Plate Reader (Perkin
Elmer, Norwalk, CT). Serum titers were expressed as the reciprocal of the dilution that yielded
a half-maximal value of absorbance at 405 nm (A405). Enzyme immunological units (EIU)
were calculated from the absorbance values using the formula:
(17,23). Those samples with EIU scores two standard deviations above the mean for the entire
set of sera were considered positive for reactivity against Cdt.
To determine antibody responses against each of the individual subunit proteins dose–response
curves were obtained. Bound subunit proteins were detected with a 1:3000 dilution of anti-
His-Tag mAb (Novagen) in PBS-1% bovine serum albumin followed by a 1:3000 dilution of
anti-mouse IgG horseradish peroxidase conjugate (Amersham Biosciences, Piscataway, NJ)
for 1 h at room temperature. The plates were developed with 100 μl horseradish peroxidase
substrate ABTS-100 (Rockland, Inc., Gilbertsville, PA) and read as described above. Based
on the dose–response data a subunit protein concentration of 166 ng/well was chosen for
titration of the human sera.
Serum neutralization assay
The ability of serum antibodies to neutralize the Cdt was determined using a modification of
a previously developed cell growth inhibition assay (19). Sonic extracts prepared from E.
coli BL21(DE3)(pET15bCdt) were used as the source of Cdt. Longitudinally collected samples
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from each subject were pooled at a 1:1 ratio (based on volume) to obtain enough serum for
analysis. The total volume of the pooled serum samples was adjusted with Ham’s F12 medium
to yield a 1:5 dilution and sterilized by passage through a 0.45-μm filter. Two aliquots of each
of the sterile serum preparations were mixed with appropriate volumes of Cdt-containing sonic
extracts and adjusted to a volume of 1 ml yielding a final serum dilution of 1:10 and total
protein concentrations of 15 and 35 ng protein/μl. These were then incubated at 4°C on a shaker
for 1.5 h. Chinese hamster ovary (CHO) K-1 cells were grown in T-75 tissue culture flasks in
Ham’s F12 medium, containing 5% fetal calf serum (FCS), at 37°C in the presence of 5%
CO2. After 3–4 days of growth the cells were harvested, counted and adjusted to 1 × 104 cells
per ml of medium. The CHO cells were seeded in six-well tissue culture plates (300 cells in 3
ml medium per well in triplicate) and were allowed to attach to the plates. One milliliter of
each of the Cdt-serum preparations was added to different wells of CHO cells and incubated
for 30 min at 37°C. The wells were washed with PBS and 2 ml fresh Ham’s F12 medium
containing 5% FCS was added to each well. The plates were then incubated for 6 days at 37°
C to allow colonies to form. The medium was then removed and the cells were fixed with 10%
formalin, stained with crystal violet for 10 min, dried and counted. The number of colonies per
well was expressed as colony-forming units (CFUs). A dose–response curve for wild-type
reconstituted holotoxin was also prepared using 0–2.5 μg of total protein/ml. Each sample was
analysed three times.
Statistical analyses
Data obtained from ELISA were analysed with the software package SAS version 9.1 and
descriptive findings were produced using SAS Proc Univariate. One-way repeated measures
analysis of variance with post-hoc paired comparisons was applied to determine whether there
were any statistically significant differences in the antibody response against the different
clinical groups as well as against each of the subunits. Regression analysis was applied for the
neutralization assay.
Results
Humoral antibody response of the study subjects to the Cdt
An ELISA was used to analyse 692 longitudinally collected serum samples originally obtained
from 95 previously described subjects for Cdt-binding antibody (6). All of the available
samples provided by each subject were evaluated (ranging in number from 1 to 28). A subset
of 113 samples was randomly chosen for analysis to standardize the assay as well as to identify
internal positive (reference serum) and negative (no Cdt-specific antibody) control sera. A
representative sampling of the results of this initial screen are shown in Fig. 1A, B. Serum
samples 692 and 30 were selected to serve as positive and negative controls, respectively,
throughout subsequent analyses. The titers (reciprocal of the dilution that yielded a half-
maximal A405 value) of the individual samples were distributed over a wide range of values.
For example, sample 267 had a relatively low titer (approximately 800) in contrast to samples
187, 188 and 193 which had titers greater than 3200. There was significant variability in the
absorbance values of the same reference and negative control sera among the ELISA plates.
To normalize the responses of all of the serum samples to the Cdt and to control for the
variability inherent in the examination of large numbers of ELISA plates EIU scores were
calculated and used to express the results. Serum dilutions from 1:800 to 1:3200 were
evaluated. A statistical analysis was performed by evaluating the EIU scores with the Proc
Univariate report with a cut-off value of 95%. The reference and negative control sera were
excluded from the statistical analysis because it was necessary to use them to calculate the EIU
scores. Fig. 2 shows the distribution of the EIU scores at the dilution 1:1600; this dilution was
chosen because it was at this dilution that the EIU scores approached a normal distribution. A
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majority of the samples exhibited EIU scores between 50 and 150 while a limited number had
relatively higher values. Only those samples with EIU scores in the 95th percentile and higher
were considered seropositive. The horizontal line in Fig. 2 depicts the cut-off value of EIU 200
(95th percentile) and separates the seropositive from the seronegative samples. Using this
approach it was determined that 35 out of 692 samples contained relatively high levels of Cdt-
binding antibody (EIU scores ranging from 203 to 462). These sera originated from 14 of the
95 individuals from whom blood was collected. These will be referred to as seropositive
subjects 1 through 14. Therefore, only 14.7% of the 95 subjects exhibited significant serum
Cdt-binding activity as defined by the criteria established for the ELISA.
Distribution of the seropositive and seronegative sera among the diagnostic categories is shown
in Fig. 3. Although the majority of positive samples (10/14) were obtained from clinically
healthy individuals, the percentages of seropositive subjects within each group were very
similar. Interestingly, only a small percentage of the LAP subjects (12.5%) were seropositive
with respect to Cdt-binding antibody. The serum sample from each subject exhibiting the
highest EIU score was further analysed by ELISA extending the dilutions up to 1:204,800 (data
not shown). Whereas most of the positive sera lost binding activity at dilutions between 1:6400
to 1:12,800, there were two samples (324 and 688) that exhibited binding activity up to a
dilution slightly greater than 1:51,200. These sera were from a healthy subject (324) and a
conversion patient (688).
With the significant disparity in the number of samples collected per seropositive subject
(ranging from two to 16) no consistent pattern of anti-Cdt antibody production was detected
over time. Only two of the 14 seropositive subjects provided three or more positive samples:
seropositive subject 7 (nine out of 14) and seropositive subject 11 (10 out of 11) (data not
shown). Interestingly, seropositive subject 7 developed LAP during the study and eight of the
nine positive samples were obtained after the single conversion event. In contrast, seropositive
subject 11 was a control subject who remained clinically healthy throughout the study.
Binding of serum IgG antibody to individual Cdt subunits
The initial phase of our analysis allowed us to identify serum samples that exhibited significant
Cdt-binding activity. These experiments were conducted with intact holotoxin so it is unclear
whether the antibodies were specific for conformation-dependent epitopes formed via the
interaction of the three subunits or, alternatively, for epitopes unique to the individual subunits.
Therefore, the 14 serum samples with the highest EIU scores (dilution of 1:1600) against the
reconstituted toxin were further analysed by ELISA for IgG antibodies against each one of the
subunits. This approach not only allowed us to map the specificity of the antisera but also to
determine whether the antibody responses were skewed towards any one of the subunits. Equal
volumes of serum from all the positive samples were pooled and used as the reference serum
in these analyses. The negative control serum remained the same as in the previous ELISA
experiments. EIUs were determined for each of the individual high-titer antisera (diluted
1:1600) to the individual Cdt subunits (Fig. 4). Statistical analysis showed that the mean EIU
scores for CdtA, CdtB, and CdtC were not significantly different (α > 0.05).
Serum neutralization of Cdt
The results derived from the ELISAs are purely quantitative in nature because they do not
provide information regarding the functional characteristics of the Cdt-binding antibody. To
address this issue experiments were conducted to determine whether the serum antibodies could
neutralize the toxin. Neutralizing activity was defined as the ability of the sera to block Cdt-
mediated growth inhibition of CHO cells as measured in a colony-forming assay. Growth
inhibition was determined by calculating the number of CFUs in Cdt-treated cultures relative
to untreated control cultures. To have sufficient volumes of antisera to conduct this series of
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experiments it was necessary to pool the sera collected at different time-points for each of the
14 seropositive subjects. The CHO cells were exposed to recombinant Cdt, Cdt preincubated
with negative control antisera (1:10 final dilution) or Cdt preincubated with pooled positive
antisera (1:10 final dilution). Untreated CHO cells served as the negative control. Additionally,
extract prepared from wild-type E. coli BL21(DE3) had no effect on the growth of CHO cells
(data not shown). Preliminary assays showed that 15 ng protein/μl extract consistently resulted
in a 50% reduction in CFU relative to controls and was therefore chosen as the appropriate
concentration for the neutralization assays (data not shown). The cells were exposed to the
various preparations for 30 min. A representative assay is shown in Fig. 5A. In this example,
there was a slight reduction in the number of CFUs in cultures exposed to Cdt extract
preincubated with one of the 14 pooled positive antisera (Panels a versus d). Cells exposed to
Cdt extract preincubated with the negative control serum exhibited a significant reduction in
the number of CFUs (Panels a versus c). To eliminate tissue culture plate-to-plate variation,
the percentage of neutralization of the cytotoxic effect, relative to that of the positive control,
was calculated for each of the 14 pooled serum samples. All of the samples exhibited some
neutralizing activity ranging from an approximately 20% to a 75% reduction of the cytotoxic
effect observed in the absence of serum (Fig. 5B). There was no correlation between the extent
of serum neutralizing activity and the clinical status of each of the 14 seropositive subjects.
When the percentage inhibition of cell death was plotted against the mean EIU score for each
subject an inverse relationship was observed; higher percentages of neutralizing activity
correlated with lower mean EIU scores (P = 0.02, data not shown).
Discussion
It is the general consensus that patients with LAP have elevated levels of serum antibodies
against various antigens of A. actinomycetemcomitans (14). The goal of this study was to
determine whether this observation also pertains to a recently identified A.
actinomycetemcomitans virulence factor, Cdt. The results showed no statistically significant
difference in the mean Cdt-specific antibody levels between subjects with a history of LAP or
with active LAP and healthy individuals. Therefore, the hypothesis that individuals with a
history of LAP or with active LAP have higher levels of antibody to Cdt was rejected. There
are no other reports in the literature addressing the A. actinomycetemcomitans Cdt-specific
antibody response in LAP patients. However, our finding is in agreement with that reported
by Johansson et al. (9), who reported that the levels of Cdt-specific serum antibodies detected
in the patients with chronic periodontitis were essentially equivalent to those of age-matched
periodontally-healthy control subjects.
Data derived from ELISA provides only a quantitative measurement of antibody levels in
serum. This type of information, though certainly of use, does not provide an indication of the
functional activity of the antibody. There are numerous human infectious diseases in which
microbes elicit quantitatively robust systemic humoral immune responses that fail to provide
protection, as is the case with infection by the human immunodeficiency virus (13). Hence,
more detailed analyses of the seropositive samples were conducted. They all exhibited activity
against each of the subunit proteins (CdtA, CdtB, and CdtC). There were no statistically
significant differences in the absolute amounts of antibody against the three subunits (α > 0.05).
The only report in the literature regarding the subunit specificity of the human antibody
response to Cdt is that of Mbwana et al. (20) who evaluated responses against the Cdt from H.
ducreyi in patients with chancroid. The results of that study showed that the only subunit
recognized by all of the sera was CdtA. Conversely, our results indicated a far more diverse
response composed of antibody reactive with each of the three subunits. This suggests that
none of the subunits exhibit so-called immunodominance. With regards to neutralizing activity,
all 14 samples were found to neutralize the A. actinomycetemcomitans Cdt in a colony-forming
assay, though some more efficiently than others. This observation is similar to that reported
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by Abuoun et al. (1) who detected Cdt-neutralizing antibody in humans naturally infected with
toxin-producing strains of C. jejuni.
In an attempt to further elucidate the implications of the results described in this paper the data
were considered in relation to microbiological data previously reported by our laboratory (6).
That study characterized A. actinomycetemcomitans isolated from the same individuals who
provided sera for the current study. The bacterium was isolated from five of the 10 seropositive
periodontally healthy subjects and all of the isolates belonged to restriction fragment length
polymorphism (RFLP) groups found to produce minimal if any Cdt. In contrast, A.
actinomycetemcomitans belonging to RFLP groups associated with high levels of Cdt
production were isolated from six of nine seronegative conversion subjects and eight of 12
seronegative probands diagnosed with LAP. Taken together these observations suggest that
individuals who mount a significant anti-Cdt neutralizing antibody response directed against
all three subunits of the holotoxin are immune to highly cytotoxic strains of A.
actinomycetemcomitans. With respect to the three seropositive subjects who converted to
disease a majority of the positive samples (nine out of 11) were obtained at time-points
following their clinical conversions. None of these individuals exhibited further breakdown
during the study. This may in part explain why a majority of the seropositive subjects did not
develop LAP and of those that did, so-called ‘burnout’ of the disease occurred following
induction of the anti-Cdt response. Additionally, the presence of neutralizing antibody in the
serum of individuals known to be colonized by Cdt-producing strains of A.
actinomycetemcomitans indicates that the toxin is produced during natural infection of humans.
Why some individuals develop a protective anti-Cdt response and others do not is a matter of
conjecture. In all likelihood both bacterial and host factors are involved in this process. Since
Cdt is known to have a cytotoxic effect on lymphocytes and plasmacytoid cells it is possible
that the toxin itself down-modulates the production of antibody by both direct and indirect
effects on B cells (23,24,26). Clearly, genetic regulation of the anti-Cdt antibody response must
be considered. The specificity of an antibody molecule is determined by the amino acid
sequences of the variable regions of the light and heavy chain proteins. It is therefore plausible
that some individuals inherit the genetic elements which encode ‘protective’ specificities while
others produce antibody against biologically irrelevant portions of the Cdt (or the component
subunit proteins). This can only be investigated via a molecular genetic evaluation of the genes
encoding the variable regions of ‘protective’ antibodies, which is well beyond the scope of the
current study.
Despite the fact that a larger sample size would allow a more powerful analysis of the A.
actinomycetemcomitans Cdt-specific antibody response in LAP, there are points to be taken
from this study. First, the fact that an individual is diagnosed with the disease and known to
be infected with a toxin-producing strain of the organism does not infer the presence of Cdt-
specific serum antibody. Second, and possibly more important, high titers of anti-Cdt antibody
do not imply potent functional activity. It could be argued that high titers of antibody against
the Cdt result from constant stimulation of the response as the result of an inability to neutralize
the toxin and/or eliminate the bacterium. Finally, when considered along with the previously
reported microbiological data, as described above, the results of the current study suggest that
low titer sera with potent Cdt-neutralizing activity may represent one aspect of a protective
response against A. actinomycetemcomitans.
In summary, these results demonstrate that the Cdt is capable of inducing a neutralizing
antibody response in humans naturally infected with A. actinomycetemcomitans. The data from
this study provide a foundation for extending studies of the humoral antibody response to the
A. actinomycetemcomitans Cdt. Such endeavors will help clarify the role of Cdt and toxin-
specific antibody in the pathogenesis of LAP.
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Fig. 1.
Quantification of serum antibody binding to the cytolethal distending toxin (Cdt) holotoxin.
Sera were serially diluted from 100 to 3200 and added to enzyme-linked immunosorbent assay
plates coated with reconstituted Cdt. Values of optical density at 405 nm (OD405) are plotted
against the reciprocal of the corresponding dilution factor. (A) and (B) show representative
titration curves of samples chosen from the 692 that were analysed (designated by number).
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Fig. 2.
Distribution of enzyme immunological units (EIU) scores representing cytolethal distending
toxin (Cdt) -binding activity in sera at a 1:1600 dilution. To account for day-to-day variations
in the enzyme-linked immunosorbent assays all data were converted EIU scores. The scores
measured at a 1:1600 were chosen for evaluation because they most closely approached a
normal distribution. The horizontal line depicts the cut-off value of EIU 200 (95th percentile)
and separates the positive from the negative samples.
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Fig. 3.
Distribution of seropositive individuals among the three diagnostic categories. Of the 14
seropositive subjects, 10 remained clinically healthy, three were diagnosed with localized
aggressive periodontitis (LAP) and one with chronic periodontitis. The differences in the
percentages of seropositive subjects detected in each category were not statistically significant
(P > 0.05).
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Fig. 4.
Antibody binding to the individual cytolethal distending toxin (Cdt) subunit proteins (CdtA,
CdtB, and CdtC). Samples from the 14 seropositive individuals were further evaluated by
enzyme-linked immunosorbent assay on plates coated with the individual Cdt subunit proteins.
Mean enzyme immunological unit (EIU) scores were calculated for the samples provided by
each subject at a 1:1600 dilution. Although the patterns of reactivity against the three proteins
differed between individuals there was not a statistically significant difference in the overall
binding to the proteins (P > 0.05).
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Fig. 5.
Neutralization of cytolethal distending toxin (Cdt) -mediated growth inhibition of Chinese
hamster ovary (CHO) cells. A modified colony-forming assay was used to evaluate Cdt
neutralizing activity in pooled samples of serum from each of the 14 seropositive subjects. (A)
A typical assay in which wells contained: (a) untreated CHO cells, (b) Cdt-treated cells, (c)
cells treated with Cdt that had been preincubated with negative control serum, and (d) cells
treated with Cdt that had been preincubated with serum from a seropositive subject. (B) The
percentage neutralization of Cdt-mediated growth inhibition of CHO cells for each of the 14
seropositive subjects.
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